Stock AUTL AUTOLUS THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Autolus Therapeutics plc

Equities

AUTL

US05280R1005

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
4.02 USD +2.55% Intraday chart for Autolus Therapeutics plc +3.88% -37.58%
May. 23 Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
May. 21 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
GL
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
GL
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
AQ
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
GL
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
AQ
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
GL
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
GL
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
GL
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
AQ
Autolus Therapeutics Announces Changes to its Board of Directors
GL
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
GL
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
AQ
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
GL
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
AQ
Autolus Therapeutics announces publication in Blood Cancer Journal
GL
Autolus Therapeutics announces publication in Blood Cancer Journal
AQ
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
GL
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
AQ
Autolus Therapeutics announces publication in Nature Communications 
GL
Autolus Therapeutics announces publication in Nature Communications 
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AUTL Stock
  4. News Autolus Therapeutics plc
  5. Press Releases